Results 161 to 170 of about 7,252,224 (344)

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

open access: yesNature, 2009
S. Purcell   +6 more
semanticscholar   +1 more source

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

open access: yesFEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson   +7 more
wiley   +1 more source

Global variation in copy number in the human genome

open access: yesNature, 2006
R. Redon   +49 more
semanticscholar   +1 more source

Evaluation and Interpretation of Genetic Effective Population Size of Delta Smelt from 2011–2014

open access: yesSan Francisco Estuary and Watershed Science, 2017
https://doi.org/10.15447/sfews.2017v15iss2art5Delta Smelt have collapsed demographically, but little is known about their current genetic status. We used 12 microsatellite loci to evaluate two measures of the effective population size (Ne) of Delta ...
Amanda J. Finger   +3 more
doaj  

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

open access: yesMolecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou   +5 more
wiley   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Variation in Variation Measurement: A Mapping Review of Methods to Study Clinical Variation. [PDF]

open access: yesJ Eval Clin Pract
Quinn AE   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy